RFL
Rafael Holdings, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Rafael has 10 disclosed suppliers and 3 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Rafael Holdings, Inc.
1.01
+0.01 · +0.53%
post 1.12 +11.62%
SentenceDuring the year ended July 31, 2026, one major customer from this revenue stream accounted for 34% of total revenues.
RFL 10-Kaccession 0001213900-26-113659
SentenceCornerstone maintains a low single-digit royalty agreement with Altira Capital and Consulting, LLC ("Altira"), pursuant to which Cornerstone is granted sole ownership of certain patents directed to lipoic acid derivatives and other technology.
RFL 10-Kaccession 0001213900-26-113659
SentenceOur main supplier of specialty cyclodextrins and complexes, Cyclodextrin Research & Development Laboratory, is located in Hungary and its prices are set in Euros.
RFL 10-Kaccession 0001213900-26-113659
SentenceSince then, we have sought partners for Farber programs and have entered into a license agreement for one of its technologies that is in the pre-clinical research stage with the Ludwig Institute of Cancer Research and have transferred majority ownership of another one of its technologies, SHMT, to a new company, Forme Therapeutics, that is being managed by Dr. Joshua Rabinowitz with the goal of developing SHMT while seeking out external investment and partnerships.
RFL 10-Kaccession 0001213900-26-113659
SentenceIn addition, on April 16, 2026, Cyclo entered into an exclusive, worldwide, royalty-bearing Patent License Agreement with the Massachusetts Institute of Technology ("MIT") for certain patent rights relating to small molecules to improve myelination in Alzheimer's disease and APOE4 carriers, under which Cyclo may develop and commercialize products containing hydroxypropyl-β-cyclodextrin for Alzheimer's disease.
RFL 10-Kaccession 0001213900-26-113659
SentenceCash used in investing activities for the year ended July 31, 2026 of $0.7 million was primarily due to the purchase of preferred shares and warrants from Nina Medical Ltd. for $0.8 million, offset by proceeds of $0.1 million from the sale of property and equipment.
RFL 10-Kaccession 0001213900-26-113659
SentenceBarer's majority owned subsidiary, Farber Partners, LLC ("Farber"), was formed around one such agreement with Princeton University's Office of Technology Licensing ("Princeton") for technology from the laboratory of Dr. Joshua Rabinowitz, in the Department of Chemistry, Princeton University, for an exclusive worldwide license to its SHMT (serine hydroxymethyltransferase) inhibitor program.
RFL 10-Kaccession 0001213900-26-113659
SentenceCornerstone maintains (i) an exclusive license agreement with the Research Foundation of the State University of New York at Stony Brook, or RF, granting Cornerstone the exclusive right to make, use and sell products covered under specified technology relating to lipoic acid derivatives with the right to grant sublicenses.
RFL 10-Kaccession 0001213900-26-113659
SentenceCornerstone maintains (i) an exclusive license agreement with the Research Foundation of the State University of New York at Stony Brook, or RF, granting Cornerstone the exclusive right to make, use and sell products covered under specified technology relating to lipoic acid derivatives with the right to grant sublicenses.
RFL 10-Kaccession 0001213900-26-113659
SentenceLipoMedix also maintains an exclusive license agreement with Shaare Zedek Scientific Company, the technology transfer arm of Shaare Zedek Medical Center ("SZMC"), granting LipoMedix the exclusive right to license any new intellectual property developed at SZMC relating to the mitomycin lipophilic prodrug and its liposomal formulation (Promitil ® ) with the right to grant sublicenses.
RFL 10-Kaccession 0001213900-26-113659
SentenceLipoMedix maintains an exclusive license agreement with Yissum Research and Development Company, the technology transfer arm of the Hebrew University of Jerusalem granting LipoMedix the exclusive right to make, use and sell products covered under specified patents relating to the mitomycin lipophilic prodrug and its liposomal formulation (Promitil ® ) with the right to grant sublicenses.
RFL 10-Kaccession 0001213900-26-113659
SentenceAs of July 31, 2026, the space is fully leased to two tenants; one of which is an IDT subsidiary.
RFL 10-Kaccession 0001213900-26-113659
SentenceFarber and Ludwig also entered into a license agreement for its T-Cell Nutrient technology, and Farber will receive a royalty upon the achievement of certain milestones and sales related to the product.
RFL 10-Kaccession 0001213900-26-113659
Expected move
No implied move.